Cantor Fitzgerald Comments on Humana FY2026 Earnings

Humana Inc. (NYSE:HUM) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Humana in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. James anticipates that the insurance provider will post earnings of $14.58 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $290.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $7.23 earnings per share.

Several other analysts have also recently commented on HUM. Truist Financial decreased their price target on shares of Humana from $325.00 to $305.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, May 1st. Wall Street Zen raised shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Sixteen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $284.48.

Humana Trading Down 0.5%

Shares of HUM opened at $231.95 on Tuesday. The firm has a market cap of $27.99 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a 50 day simple moving average of $252.19 and a two-hundred day simple moving average of $264.01.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.53%. Humana’s dividend payout ratio (DPR) is 25.04%.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the fourth quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 46 shares in the last quarter. LFA Lugano Financial Advisors SA lifted its stake in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. Finally, OFI Invest Asset Management bought a new position in Humana during the 4th quarter worth about $33,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.